Premium
Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases
Author(s) -
Serreau Raphael,
Luton Dominique,
Macher MarieAlice,
Delezoide AnneLise,
Garel Catherine,
JacqzAigrain Evelyne
Publication year - 2005
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.2004.00525.x
Subject(s) - pregnancy , medicine , fetus , obstetrics , prospective cohort study , population , gynecology , biology , genetics , environmental health
Objective Angiotensin II type 1 receptor antagonists (ARA). Interacted with the renin–angiotensin system, and the present study was undertaken to examine their fetal and neonatal toxicity when taken by the mother during pregnancy. Design Prospective follow up of pregnant women exposed to an ARA during early pregnancy. Setting The present study was conducted in the departments of Paedriatric Pharmacology of the University hospital Robert Debré in Paris, France. Population Ten women exposed to an ARA during early pregnancy. Methods Prospective follow up. Main outcome measure Fetal ultrasonography and outcome of pregnancy. Results Prenatal ultrasonography showed abnormal features in five cases (oligoamnios related to fetal tabular dysgenesis, fetal dysmorphia and renal abnormalities). Outcome of pregnancy was as follows: three induced abortions, two stillbirths (twin pregnancy), one neonate presenting with dysmorphia and renal disease and five neonates with an uneventful development. Conclusion Women of reproductive age should be advised of the possible hazards of ARA and treatment should be stopped as soon as pregnany has been documented.